Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

Drug Discov Today. 2005 Aug 1;10(15):1041-7. doi: 10.1016/S1359-6446(05)03512-9.


Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology*
  • Receptor, IGF Type 1 / antagonists & inhibitors*
  • Signal Transduction


  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Receptor, IGF Type 1